Welcome to our dedicated page for COVALON TECHS news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on COVALON TECHS stock.
Covalon Technologies Ltd. is a global leader in researching, developing, and commercializing healthcare technologies that save lives worldwide. With patented products and services, Covalon addresses medical device companies, healthcare providers, and individual consumers' advanced healthcare needs. Specializing in wound care, tissue repair, infection control, disease management, medical device coatings, and biocompatibility, Covalon's technologies prevent, detect, and manage various medical conditions.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announces its participation in the 2024 ANCC National Magnet Conference in New Orleans from October 30 to November 1, 2024. The company will showcase its vascular access solutions at Booth 562, featuring products like VALGuard®, IV Clear®, CovaClear® IV, and SurgiClear®. These innovations include antimicrobial dressings and line guards designed to protect IV sites and improve patient comfort. The conference provides an opportunity for Covalon to connect with nursing professionals and demonstrate their commitment to compassionate patient care through innovative medical technology.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announces its participation in the 2024 Association for Vascular Access (AVA) Annual Scientific Meeting from September 28 to 30 in Colorado. The company will showcase its compassionate vascular access solutions at booth #523, including a new range of CovaClear® IV Vascular Access Dressings.
Covalon's patented products on display include:
- VALGuard® - a transparent line guard
- SurgiClear® - a dual antimicrobial clear silicone adhesive dressing
- IV Clear® - a dual antimicrobial clear IV securement dressing
- CovaClear® IV - a soft silicone adhesive clear IV dressing
CEO Brent Ashton emphasizes the company's commitment to enhancing patient comfort and improving vascular access clinical care. Attendees can book appointments with Covalon representatives to learn more about their innovative solutions.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced the successful redemption of warrants from its 2019 private placement. Company directors exercised 852,700 warrants, generating approximately $1.7 million CAD, while long-term shareholders exercised 1,875,800 warrants, bringing in about $3.8 million CAD. This brings Covalon's net cash position to approximately $16.0 million CAD.
CEO Brent Ashton expressed satisfaction with the confidence shown by insiders and long-term shareholders in Covalon's future value. The warrants, originally set to expire on September 18, 2024, were issued as part of a private placement in September 2019. Following this exercise, Covalon now has 27,398,077 common shares outstanding, with insiders beneficially owning and controlling 14,194,323 shares, representing about 51.8% of the company's outstanding shares.
Covalon Technologies (TSXV:COV, OTCQX:CVALF), an advanced medical technologies company, will be presenting at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024, at 10:00 AM PST. Brent Ashton, CEO of Covalon, will host the presentation and answer questions.
The live presentation can be accessed via webcast at https://www.webcaster4.com/Webcast/Page/3056/510941. One-on-one meetings will be conducted in person at the Fairmont Waterfront Vancouver. If unable to attend live, the presentation will be available on the conference event platform under the 'Agenda' tab at https://planetmicrocapshowcase.com/agenda.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) reported strong Q3 fiscal 2024 results, with significant year-on-year growth. Key highlights include:
- Q3 revenue of $9.2 million, up 47% year-on-year
- Q3 gross profit of $5.4 million, up 51% year-on-year
- Q3 EBITDA of $1.7 million and adjusted EBITDA of $2.4 million
- Earnings per share (EPS) of $0.06
The company's performance was driven by expansion in US hospitals and stronger demand for its collagen dressing. Gross margin improved to 59%, while operating expenses decreased due to restructuring efforts. The company's CEO, Brent Ashton, emphasized that these results demonstrate progress on key priorities and the success of foundational work to strengthen Covalon.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced it will release its Q3 Fiscal 2024 financial results on Wednesday, August 21, 2024, before markets open. The company will hold a conference call and webcast to discuss these results on the same day at 8:30am ET.
Participants can join the webcast or dial in to the conference call using the provided links and numbers. The call will include a Q&A session where participants can ask questions to Company management. A recording of the call will be available on Covalon's website under the Investors tab. Financial statements and MD&A can be accessed on SEDAR PLUS and the company's website.
Covalon Technologies announced strong Q2 fiscal 2024 results, with a 16% year-on-year revenue increase to $8.4 million. The company achieved an EBITDA of $1.7 million, adjusted EBITDA of $2.5 million, and an EPS of $0.06. US product segment revenue surged by 54%, contributing to the overall growth. Gross margins improved to 63%, the highest in recent company history. Operating expenses were reduced by 22% compared to the previous year, further boosting profitability. Additionally, the company noted a significant reduction in development and consulting services revenue to $0.06 million for the half-year period, down 97% from the prior year. A conference call to discuss these results is scheduled for May 29, 2024.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) will release its Q2 Fiscal 2024 financial results on May 29, 2024, before markets open. A conference call and webcast to discuss these results will be held the same day at 8:15am ET. Participants can join the call by dialing the provided phone numbers or access the live webcast via a link. The conference call will include a Q&A session where management will answer questions. A recording will be available on the Covalon website. Financial statements and MD&A can be accessed on SEDAR PLUS and Covalon’s website.
Covalon Technologies announced its participation in the Infusion Nurses Society Annual Meeting and Exhibition in Kansas City from May 18 to May 20, 2024. At booth #420, Covalon will showcase its advanced vascular access and infection control solutions, including VALGuard, IV Clear, and CovaClear IV. These products emphasize comfort, protection, and patient safety during infusion treatments. CEO Brent Ashton highlighted the company's dedication to combining efficacy and empathy in patient care.
FAQ
What is the current stock price of COVALON TECHS (CVALF)?
What is the market cap of COVALON TECHS (CVALF)?
What does Covalon Technologies Ltd. specialize in?
Which sectors does Covalon cater to?
What is unique about Covalon's patented technologies?
Where can I find more information about Covalon Technologies Ltd.?
How does Covalon Technologies Ltd. contribute to the healthcare industry?
What is the mission of Covalon Technologies Ltd.?
Why is Covalon Technologies Ltd. considered a global leader in healthcare technologies?
How does Covalon Technologies Ltd. contribute to wound care and infection control?
What sets Covalon Technologies Ltd. apart from other healthcare technology companies?